Some considerations regarding aspirin use in the primary prevention of cardiovascular events
Keywords:
Aspirin, Primary Prevention, Cardiovascular Diseases, Secondary PreventionDownloads
References
1. Werz O, Stettler H, Theurer C, Seibel J. The 125th anniversary of aspirin—the story continues. Pharmaceuticals (Basel). 2024;17(4):437. doi: 10.3390/ph17040437.
2. World Health Organization. The selection and use of essential medicines, 2025: WHO Model List of Essential Medicines 24th list [Internet]. Geneva: OMS; 2025 [citado 2026 feb. 11]. Disponible en: https://iris.who.int/server/api/core/bitstreams/17642505-ecd3-4940-a691-4f1dfa0d835a/content
3. O'Brien CW, Juraschek SP, Wee CC. Prevalence of aspirin use for primary prevention of cardiovascular disease in the united states: results from the 2017 National Health Interview Survey. Ann Intern Med. 2019;171(8):596-598. doi:10.7326/M19-0953.
4. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1989;321(3):129-135. doi:10.1056/NEJM198907203210301.
5. Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) [Internet]. 1988 [citado 2026 feb. 11];296(6618):313-6. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC2544821/pdf/bmj00270-0009.pdf
6. The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet. 1998;351(9098):233-241. doi:10.1016/S0140-6736(97)11475-1.
7. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352(13):1293-304. doi: 10.1056/NEJMoa050613.
8. Guirguis-Blake JM, Evans CV, Senger CA, O'Connor EA, Whitlock EP. Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the u.s. preventive services task force. Ann Intern Med. 2016;164(12):804-13. doi: 10.7326/M15-2113.
9. Mahmoud AN, Gad MM, Elgendy AY, Elgendy IY, Bavry AA. Efficacy and safety of aspirin for primary prevention of cardiovascular events: a meta-analysis and trial sequential analysis of randomized controlled trials. Eur Heart J. 2019;40(7):607-17. doi:10.1093/eurheartj/ehy813.
10. Zheng SL, Roddick AJ. Association of Aspirin Use for Primary Prevention with cardiovascular events and bleeding events: a systematic review and meta-analysis. JAMA. 2019;321(3):277-87. doi:10.1001/jama.2018.20578.
11. McNeil JJ, Nelson MR, Woods RL, Lockery JE, Wolfe R, Reid CM, et al. Effect of Aspirin on All-Cause Mortality in the Healthy Elderly. New Engl J Med. 2018;379(16):1519-28. doi:10.1056/NEJMoa1803955.
12. ASCEND Study Collaborative Group, Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018;379(16):1529-1539. doi: 10.1056/NEJMoa1804988.
13. Gaziano JM, Brotons C, Coppolecchia R, Cricelli C, Darius H, Gorelick PB, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018;392(10152):1036-1046. doi: 10.1016/S0140-6736(18)31924-X.
14. Mazzola M, De Caterina R. Aspirin for primary prevention: time to reconcile discrepancies. Eur J Prev Cardiol. 2025;zwaf365. doi: 10.1093/eurjpc/zwaf365.
15. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-3337. doi: 10.1093/eurheartj/ehab484.
16. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA Guideline on the primary prevention of cardiovascular disease: a report of the american college of cardiology/american heart association task force on clinical practice guidelines. Circulation. 2019;140(11):e596-e646. doi: 10.1161/CIR.0000000000000678.
17. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255-323. doi: 10.1093/eurheartj/ehz486.
18. American Diabetes Association Professional Practice Committee for Diabetes. 10. Cardiovascular disease and risk management: standards of care in diabetes-2026. Diabetes Care. 2025;49(Suppl 1):S216-S245. doi: 10.2337/dc26-S010.
19. US Preventive Services Task Force; Davidson KW, Barry MJ, Mangione CM, Cabana M, Chelmow D, et al. Aspirin use to prevent cardiovascular disease: us preventive services task force recommendation statement. JAMA. 2022;327(16):1577-1584. doi: 10.1001/jama.2022.4983.
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2026 Laura Adalys Guillen León, Yudileidy Brito Ferrer
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
